PuSH - Publication Server of Helmholtz Zentrum München: Quantitative biokinetics of titanium dioxide nanoparticles after oral application in rats (Part 2).

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Kreyling, W.G. ; Holzwarth, U.* ; Schleh, C. ; Kozempel, J.* ; Wenk, A. ; Haberl, N. ; Hirn, S. ; Schäffler, M. ; Lipka, J. ; Semmler-Behnke, M. ; Gibson, N.*

Quantitative biokinetics of titanium dioxide nanoparticles after oral application in rats (Part 2).

Nanotox. 11, 443-453 (2017)

Postprint

Research data

DOI

PMC

	Open Access Green

Abstract
Metrics
Extra information

The biokinetics of a size-selected fraction (70nm median size) of commercially available and (48)V-radiolabeled [(48)V]TiO2 nanoparticles has been investigated in female Wistar-Kyoto rats at retention timepoints 1h, 4h, 24h and 7days after oral application of a single dose of an aqueous [(48)V]TiO2-nanoparticle suspension by intra-esophageal instillation. A completely balanced quantitative body clearance and biokinetics in all organs and tissues was obtained by applying typical [(48)V]TiO2-nanoparticle doses in the range of 30-80 μg•kg(-1) bodyweight, making use of the high sensitivity of the radiotracer technique. The [(48)V]TiO2-nanoparticle content was corrected for nanoparticles in the residual blood retained in organs and tissue after exsanguination and for (48)V-ions not bound to TiO2-nanoparticles. Beyond predominant fecal excretion about 0.6% of the administered dose passed the gastro-intestinal-barrier after -h and about 0.05% were still distributed in the body at day-7, with quantifiable [(48)V]TiO2-nanoparticle organ concentrations present in liver (0.09ng•g(-1)), lungs (0.10ng•g(-1)), kidneys (0.29ng•g(-1)), brain (0.36ng•g(-1)), spleen (0.45ng•g(-1)), uterus (0.55ng•g(-1)) and skeleton (0.98ng•g(-1)). Since chronic, oral uptake of TiO2 particles (including a nano-fraction) by consumers has continuously increased in the past decades, the possibility of chronic accumulation of such biopersistent nanoparticles in secondary organs and the skeleton raises questions about the responsiveness of their defense capacities, and whether these could be leading to adverse health effects in the population at large. After normalizing the fractions of retained [(48)V]TiO2-nanoparticles to the fraction that passed the gastro-intestinal-barrier and reached systemic circulation the biokinetics was compared to the biokinetics determined after IV-injection (Part 1). Since the biokinetics patterns differ largely IV-injection is not an adequate surrogate for assessing the biokinetics after oral exposure to TiO2 nanoparticles.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

6.428

1.251